Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid 'dependence' without tolerance.
We previously showed that mouse sensory dorsal root ganglion (DRG) neurons chronically exposed to 1 microM D-ala2-D-leu5-enkephalin (DADLE) or morphine for > 2-3 days in culture become tolerant to the usual opioid inhibitory receptor-mediated effects, i.e. shortening of the duration of the calcium-dependent component of the action potential (APD), and supersensitive to opioid excitatory APD-prolonging effects elicited by low opioid concentrations. Whereas nanomolar concentrations of dynorphin(1-13) or morphine are generally required to prolong the APD of naive DRG neurons (by activating excitatory opioid receptors), femtomolar levels become effective after chronic opioid treatment. Whereas 1-30 nM naloxone or diprenorphine prevent both excitatory and inhibitory opioid effects but do not alter the APD of native DRG neurons, both opioid antagonists unexpectedly prolong the APD of most of the chronic opioid-treated cells. In the present study, chronic exposure of DRG neurons to 1 microM DADLE together with cholera toxin-B subunit (which selectively blocks GM1 ganglioside-regulated opioid excitatory, but not inhibitory, receptor functions) prevented the development of opioid excitatory supersensitivity and markedly attenuated tolerance to opioid inhibitory effects. Conversely, sustained exposure of DRG neurons to 1 nM DADLE, which selectively activates excitatory opioid receptor functions, resulted in characteristic opioid excitatory supersensitivity but no tolerance. These results suggest that 'dependence'-like properties can be induced in chronic opioid-treated sensory neurons in the absence of tolerance. On the other hand, development of some components of tolerance in these cells may require sustained activation of both excitatory, as well as inhibitory, opioid receptor functions.
Shen
K F
KF
Department of Neuroscience, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461 USA.
Crain
S M
SM
D000818:Animals; D002772:Cholera Toxin / Q000494:pharmacology; D004361:Drug Tolerance / Q000502:physiology; D016308:Enkephalin, Leucine-2-Alanine / Q000494:pharmacology*; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D009475:Neurons, Afferent / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology; D011957:Receptors, Opioid / Q000187:drug effects*; D012680:Sensitivity and Specificity; D019966:Substance-Related Disorders / Q000503:physiopathology*; D013997:Time Factors
D010446:Peptide Fragments; D011957:Receptors, Opioid; D016308:Enkephalin, Leucine-2-Alanine; D002772:Cholera Toxin